NeuroHope Therapeutics, Inc.
Early-stage biotech developing polymeric micelle nanotherapeutics for local, sustained drug and nucleic acid delivery to the central nervous system. Core work centers on an amphiphilic graft copolymer that self-assembles into micelles enabling high loading of hydrophobic small molecules, complexation of nucleic acids, surface conjugation of targeting ligands, and intrathecal/local sustained release. Preclinical programs focus on spinal cord injury and traumatic brain injury with peer-reviewed publications and multiple government-funded research awards.
Industries
Nr. of Employees
small (1-50)
NeuroHope Therapeutics, Inc.
Greenville, South Carolina, United States
Products
Rolipram-loaded polymeric micelle formulation for local CNS delivery
A micellar formulation that encapsulates the hydrophobic PDE4 inhibitor rolipram in a polymeric core to provide localized, sustained intrathecal delivery to spinal cord or brain injury sites.
Rolipram-loaded polymeric micelle formulation for local CNS delivery
A micellar formulation that encapsulates the hydrophobic PDE4 inhibitor rolipram in a polymeric core to provide localized, sustained intrathecal delivery to spinal cord or brain injury sites.
Services
Formulation and preclinical evaluation of micelle-based sustained-release drug and nucleic acid carriers for CNS indications.
Formulation and preclinical evaluation of micelle-based sustained-release drug and nucleic acid carriers for CNS indications.
Expertise Areas
- Nanoparticle drug delivery
- Polymeric micelle formulation
- CNS-localized drug delivery (intrathecal)
- Nucleic acid delivery
Key Technologies
- Amphiphilic graft copolymer micelles (PLGA-graft-PEI)
- Hydrophobic drug encapsulation in polymeric cores
- Cationic polymer–nucleic acid complexation
- Covalent ligand conjugation to particle surfaces
News & Updates
Listed patents US 10,232,050 B1 and US 11,633,355 B2 covering multifunctional particle and methods of use.
Department of Defense SBIR Phase I award for development of dexamethasone nanotherapeutics for traumatic brain injury, awarded February 2025 ($250,000).
Multiple active and past NIH R01 and R21 awards and state/foundation grants supporting preclinical and translational research in spinal cord injury, pain regulation, and nanotherapeutic development.
Listed patents US 10,232,050 B1 and US 11,633,355 B2 covering multifunctional particle and methods of use.
Department of Defense SBIR Phase I award for development of dexamethasone nanotherapeutics for traumatic brain injury, awarded February 2025 ($250,000).
Multiple active and past NIH R01 and R21 awards and state/foundation grants supporting preclinical and translational research in spinal cord injury, pain regulation, and nanotherapeutic development.